#United States #Cambridge #Marengo Therapeutics #Invikafusp Alfa #ESMO 2026

Marengo Therapeutics Unveils Phase 2 STARt-001 Results at ESMO 2026

Marengo Therapeutics, a company focusing on innovative precision immunotherapies, announced new findings for its investigational drug, Invikafusp Alfa, at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain. This Phase 2 clinical trial, part of the STARt-001 study, emphasizes the tissue-agnostic efficacy of the drug in treating patients with high tumor mutation burden (TMB-H) solid tumors that have shown resistance to common immune checkpoint blockade therapies.

Key Findings from STARt-001

During the presentation, impressive results highlighted that the therapy generated objective responses across eight different tumor types, including:

• - Breast cancer
• - Colorectal cancer
• - Endometrial cancer
• - Gastric cancer
• - Head and neck cancers
• - Non-small cell lung cancer
• - Bladder cancer
• - Gastroesophageal junction cancers

Out of 62 evaluable patients classified as having heavily pretreated TMB-H solid tumors, tumor shrinkage was documented in 56% of cases, contributing to an 18% objective response rate (ORR) and an impressive 60% disease control rate (DCR). Notably, both patients with previous immunotherapy treatment and those new to such therapies exhibited responses, showcasing a broad spectrum of effectiveness.

Understanding the Impacts

Dr. Elena Garralda, the principal investigator of the study, expressed optimism about these results, acknowledging the unmet medical needs of patients facing limited treatment options after immune checkpoint blockade therapies. The findings also support the hypothesis that Vβ T-cell activation can produce significant immune responses independent of the PD-1 pathway, potentially invigorating treatment paradigms for several difficult-to-treat solid tumors.

Implications for Future Therapy

The results presented not only reinforce the rationale for investigating Invikafusp Alfa across multiple cancer types but also highlight its first-in-class nature as a dual T-cell agonist. This innovative mechanism of action expands the therapeutic landscape, fundamentally aiming to restore and enhance antitumor immunity. With two Fast Track Designations from the FDA already granted for this agent for colorectal cancer and a broader indication for TMB-H solid tumors, Marengo anticipates pushing forward with clinical strategy enhancements to capitalize on this exciting avenue.

Additionally, further analyses are planned, with interim results from related studies expected soon, illustrating the potential to integrate Invikafusp Alfa as a significant player in the immuno-oncology framework.

Marengo's ambitious goals for advancing this compound mirror a broad vision in combating cancer and improving treatment outcomes. In light of these developments, the medical community and patients alike will keep a close watch on Invikafusp Alfa's journey through subsequent trials, pairing it with various therapies to maximize its effectiveness against challenging cancers.

Overall, Marengo Therapeutics continues to forge ahead in the immunotherapy space, poised to harness the advancements in T-cell biology to reshape cancer treatment paradigms globally.